Stock Events

Stock Events

Larimar Therapeutics 

€3.38
32
-€0.06-1.74% Today

Statistics

Day High
3.48
Day Low
3.38
52W High
4.98
52W Low
1.55
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.63
-0.56
-0.49
-0.42
Expected EPS
-0.45369540621
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZA71.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.27B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Larimar's focus on genetic disorders.
PTC Therapeutics
PTCT
Mkt Cap5.43B
PTC Therapeutics operates in the field of genetic disorders, particularly targeting Duchenne muscular dystrophy and cystic fibrosis, overlapping with Larimar's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap711.53M
Solid Biosciences is involved in developing therapies for Duchenne muscular dystrophy, a key area of focus for Larimar Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases and medical conditions, competing in the same space as Larimar.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.44B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare diseases, directly competing with Larimar in the niche market of genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is engaged in the development of gene-based therapies, which could potentially address the same genetic disorders as Larimar's treatments.
Editas Medicine
EDIT
Mkt Cap283.93M
Editas Medicine works on editing genes to treat genetic diseases, posing a direct competition to Larimar's gene therapy approach.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is a leading company in gene editing for the treatment of genetic diseases, competing in the same innovative space as Larimar.
uniQure N.V.
QURE
Mkt Cap1.21B
uniQure is known for its work in gene therapy targeting hemophilia, but its platform could be adapted to compete with Larimar's focus areas.

About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Show more...
CEO
Dr. Carole S. Ben-Maimon M.D.
Employees
65
Country
United States
ISIN
US5171251003

Listings

STU
DE
ZA71.STU
XNAS
US
LRMR
F
DE
ZA71.F
BOATS
BOATS
LRMR.BOATS

0 Comments

Share your thoughts

FAQ

What is Larimar Therapeutics stock price today?▼
The current price of ZA71.STU is €3.38 EUR — it has decreased by -1.74% in the past 24 hours. Watch Larimar Therapeutics stock price performance more closely on the chart.
What is Larimar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Larimar Therapeutics stocks are traded under the ticker ZA71.STU.
Is Larimar Therapeutics stock price growing?▼
ZA71.STU stock has fallen by -8.65% compared to the previous week, the month change is a -17.16% fall, over the last year Larimar Therapeutics has showed a +55.05% increase.
When is the next Larimar Therapeutics earnings date?▼
Larimar Therapeutics is going to release the next earnings report on May 07, 2026.
What were Larimar Therapeutics earnings last quarter?▼
ZA71.STU earnings for the last quarter are -0.63 EUR per share, whereas the estimation was -0.42 EUR resulting in a -49.19% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Larimar Therapeutics have?▼
As of May 06, 2026, the company has 65 employees.
In which sector is Larimar Therapeutics located?▼
Larimar Therapeutics operates in the Health & Wellness sector.
When did Larimar Therapeutics complete a stock split?▼
Larimar Therapeutics has not had any recent stock splits.
Where is Larimar Therapeutics headquartered?▼
Larimar Therapeutics is headquartered in Bala Cynwyd, United States.